Hematological Biomarkers for Early Detection of Lung Cancer: Evaluating the Diagnostic Potential of Circulating Interleukin Levels
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms262211014 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Ouafaa Morjani und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Physical Chemistry and Biotechnology of Biomolecules and Materials, Faculty of Sciences and Techniques of Mohammedia, Hassan II Univers…. Hauptthemen laut MEDLINE: Lung Neoplasms, Biomarkers, Tumor, Early Detection of Cancer, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Institutes of Health (NIH) and the National Cancer Institute (NCI), National Institutes of Health.
Abstract (Originalsprache)
Early detection of lung cancer remains a major unmet clinical need, as most patients are diagnosed at advanced stages when curative treatment options are limited. Circulating cytokines and interleukins represent promising molecular biomarkers for the non-invasive diagnosis and monitoring of tumor development. In this study, we investigated the diagnostic potential of plasma interleukins in distinguishing early-stage non-small cell lung cancer (NSCLC) from healthy individuals and patients with chronic obstructive pulmonary disease (COPD). Quantitative analyses demonstrated significantly elevated plasma levels of IL-1RA, IL-6, IL-8, IL-10, and IL-17A in NSCLC patients compared with healthy controls. Among these, a composite biomarker panel comprising IL-6, IL-10, IL-8, and IL-1RA exhibited the highest diagnostic performance, outperforming individual cytokines and other combinations. This interleukin-based signature also differentiated NSCLC from COPD with strong specificity, underscoring its potential clinical applicability. These findings highlight the molecular and translational relevance of plasma interleukin profiling as a non-invasive diagnostic approach for early lung cancer detection, potentially enabling earlier intervention and improved patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Physical Chemistry and Biotechnology of Biomolecules and Materials, Faculty of Sciences and Techniques of Mohammedia, Hassan II University of Casablanca, Mohammedia 28800, Morocco.
- Department of Surgery, Thoracic Oncology Program, University of California, San Francisco, CA 94143, USA.
- Institute for Research in Hematology and Transplantation (IRHT), Hasenrain Hospital, 87 Avenue d'Altkirch, 68100 Mulhouse, France.
ORCID-Profile: Ouafaa Morjani, Rachid Lahlil, Hamid Lakhiari
Förderung
- the National Institutes of Health (NIH) and the National Cancer Institute (NCI)
- National Institutes of Health
Zitieren
APA
Morjani, O., Yang, Y. W., Lahlil, R., Lakhiari, H., & Alaoui, H. (2025). Hematological Biomarkers for Early Detection of Lung Cancer: Evaluating the Diagnostic Potential of Circulating Interleukin Levels. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms262211014
Vancouver
Morjani O, Yang YW, Lahlil R, Lakhiari H, Alaoui H. Hematological Biomarkers for Early Detection of Lung Cancer: Evaluating the Diagnostic Potential of Circulating Interleukin Levels. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms262211014
BibTeX
@article{Morjani2025,
author = {Morjani, Ouafaa and Yang, Yi-Wei and Lahlil, Rachid and Lakhiari, Hamid and Alaoui, Hassan},
title = {Hematological Biomarkers for Early Detection of Lung Cancer: Evaluating the Diagnostic Potential of Circulating Interleukin Levels},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms262211014}
}
EUVIMED